F&M Co.,Ltd. (TYO:4771)

Verve Therapeutics Cash Flow Statement

Financials in millions JPY. Fiscal year is April - March.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Net Income	-	2,742	2,233	2,620	2,258	1,233
Depreciation & Amortization	-	1,631	1,296	964	753	526
Loss (Gain) From Sale of Investments	-	-	-89	-	-	-
Other Operating Activities	-	-632	-658	-1,014	-467	-261
Change in Accounts Receivable	-	-127	-226	170	-441	-65
Change in Inventory	-	-1	2	-2	5	-4
Change in Accounts Payable	-	54	-25	-70	155	67
Change in Other Net Operating Assets	-	76	727	317	618	212
Operating Cash Flow	-	3,743	3,260	2,985	2,881	1,708
Operating Cash Flow Growth	-	14.82%	9.21%	3.61%	68.68%	188.03%
Capital Expenditures	-	-197	-362	-179	-178	-136
Divestitures	-	-	-	-	111	-
Sale (Purchase) of Intangibles	-	-2,571	-1,850	-1,615	-1,406	-1,066
Investment in Securities	-	-83	-179	-79	-212	-101
Other Investing Activities	-	-55	-30	-25	-15	-10
Investing Cash Flow	-	-2,906	-2,421	-1,898	-1,700	-1,313
Long-Term Debt Repaid	-	-	-	-	-24	-50
Net Debt Issued (Repaid)	-	-	-	-	-24	-50
Issuance of Common Stock	-	347	-	-	49	34
Dividends Paid	-	-572	-524	-467	-421	-405
Other Financing Activities	-	-	-	-	-1	-
Financing Cash Flow	-	-225	-524	-467	-397	-421
Miscellaneous Cash Flow Adjustments	-	-	-2	-1	-1	1
Net Cash Flow	-	612	313	619	783	-25
Free Cash Flow	-	3,546	2,898	2,806	2,703	1,572
Free Cash Flow Growth	-	22.36%	3.28%	3.81%	71.95%	250.11%
Free Cash Flow Margin	-	20.78%	19.50%	22.10%	24.86%	19.25%
Free Cash Flow Per Share	-	241.17	198.59	192.29	185.29	108.06
Cash Income Tax Paid	-	635	657	1,017	469	263
Levered Free Cash Flow	-	892.13	807	973.25	1,271	436.88
Unlevered Free Cash Flow	-	892.13	807	973.25	1,271	436.88
Change in Net Working Capital	-334	-331	-393	-177	-699	-351

Updated Jan 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.